

<b>Notification:</b>	HUM 7609
<u>Category:</u>	HCPCS - Drugs & Biologicals
Topic:	Louisiana Medicaid: HCPCS codes J1745, Q5103, Q5104, Q5109 and
_	Q5121 – infliximab and its biosimilars
What is changing? /	For providers with a specialty other than home infusion therapy or
<b>Change Description:</b>	pharmacy, we limit reimbursement of charges for HCPCS codes J1745,
	Q5103, Q5104, Q5109 or Q5121 to no more than:
	• 125 units per date of service for patients with Behcet's disease if a
	diagnosis of uveitis is not also present on the claim
	• 68 units per date of service for patients 18 or older with pyoderma
	gangrenosum if a diagnosis of regional enteritis (adult) or ulcerative
	colitis (adult) not also present on the claim
	• 68 units per date of service for patients 18 or older with a diagnosis
	of ulcerative colitis
Why is Humana making this change?	The limitations above are established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	compendia.Note: The limitations described above are based on
	maximum dosages established in milligrams. If any units are denied,
	the provider may dispute the decision through the appropriate
	process. The provider may submit information, including medical
	notes showing the patient's body weight, that substantiates the
	medical necessity of the additional units.
<u>Language:</u>	<u>English</u>
Impacted Products:	Medicaid- Louisiana